Swing Trading

← Return to all swing-trade opportunities

ONC — Oversold Bullish Reversal

Status: Watch

Scanner score: 20.0/100

Why this was flagged

ONC was identified as a bullish technical setup based on the Oversold Bullish Reversal pattern. The scanner found a score of 20.0/100 using trend alignment, momentum, price action, volume, and risk-management rules.

Trade framework

Current price$346.51
Entry zone$346.51 – $348.76
Stop-loss / invalidation$334.70
Target 1$370.12
Target 2$381.93
Reward/risk2.00:1
Suggested holding windowAbout 2–8 trading days; reversal setups should work relatively quickly.
FoundSep 11, 2026 10:50 pm
Potential expirationSep 21, 2026 10:50 pm
Entry plan: Consider a limit order only within the displayed entry zone. If price does not enter that range, skip the trade rather than chasing it.

Position-sizing example

Reference entry$347.63
Planned risk per share$12.93
Example: $100 planned risk7 shares
Example: $250 planned risk19 shares

These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.

Exit plan

  1. Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
  2. Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
  3. Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
  4. Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
See on TradingViewSee on Yahoo FinanceResearch on Morningstar

Technical chart

Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.

$250.54$285.82$321.10$356.38$391.66Target 2 $381.93Target 1 $370.12Entry high $348.76Entry low $346.51Stop $334.70May 5, 2026Sep 11, 2026
CloseSMA 20EMA 20SMA 50SMA 200Entry zoneStop-lossTargets

$1,000 educational outcome examples

Example reference entry$347.63
Example fractional shares2.88
If Target 1 is reached$1,064.69 value (+6.5%)
If Target 2 is reached$1,098.66 value (+9.9%)
If the stop-loss is reached$962.81 value (-3.7%)

These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.

Easy explanation for new investors

A plain-English explanation is being prepared from this scanner data. Please check back shortly.

Recent news context

This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.

Overall context: Positive (High confidence)

BeiGene reported a substantial 627% increase in its first-half 2026 net profit to 3.27 billion yuan, supported by robust global sales of its key product, Zanubrutinib, which reached 16.13 billion yuan. The company also recorded improved gross margins, increased revenue from Amgen-authorized products and tislelizumab, and better operating efficiency. Recent regulatory progress includes FDA approval for a new indication for tislelizumab, while the company has lifted its full-year revenue guidance, expressing confidence in Zanubrutinib's sustained growth.

Potentially supportive context

  • First-half 2026 net profit surged 627% to 3.27 billion yuan.
  • Global sales of Zanubrutinib reached 16.13 billion yuan, contributing to revenue growth.
  • The company received FDA approval for a new indication for tislelizumab and raised its full-year revenue guidance.

Risks and caution items

  • The current stock price of 346.51 is above the stop-loss level of 334.70, indicating technical exposure.
  • The oversold bullish reversal technical setup, with a technical score of 20, suggests the stock may face volatility in the short term.

Latest reviewed article: Aug 30, 2026 8:24 pm

Recent related articles

BeiGene H1 net profit surges 627% as global Zanubrutinib sales top 16.1 billion yuanfinance.biggo.com · Aug 30, 2026 · Provider label: Bullish

BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven by strong global sales of its core product, Zanubrutinib, which reached 16.13 billion yuan. The company also saw increased revenue from Amgen-authorized products…

Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.

Scanner confirmations

  • RSI is near oversold territory with bullish candle confirmation.
Important: This is an automated educational screening result, not a buy recommendation. Confirm price, liquidity, earnings dates, news, and your own risk before entering any trade.
Scroll to Top